31,093 Shares in Dr. Reddy's Laboratories Limited (NYSE:RDY) Acquired by Bridgewater Advisors Inc.

Bridgewater Advisors Inc. acquired a new stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 31,093 shares of the company's stock, valued at approximately $474,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its position in shares of Dr. Reddy's Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after purchasing an additional 137 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy's Laboratories in the third quarter worth about $60,000. Van ECK Associates Corp raised its position in shares of Dr. Reddy's Laboratories by 64.3% during the third quarter. Van ECK Associates Corp now owns 823 shares of the company's stock worth $64,000 after purchasing an additional 322 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 83.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company's stock valued at $115,000 after purchasing an additional 657 shares in the last quarter. Finally, Glenmede Trust Co. NA acquired a new position in shares of Dr. Reddy's Laboratories in the 3rd quarter valued at approximately $207,000. Institutional investors and hedge funds own 3.85% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on RDY shares. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Finally, Barclays reduced their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy's Laboratories Stock Up 0.5 %

RDY stock traded up $0.08 during midday trading on Monday, hitting $14.91. The company's stock had a trading volume of 2,028,244 shares, compared to its average volume of 1,369,127. The company's fifty day moving average price is $14.86 and its 200 day moving average price is $15.55. Dr. Reddy's Laboratories Limited has a twelve month low of $13.47 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The stock has a market capitalization of $12.44 billion, a P/E ratio of 23.82 and a beta of 0.51.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.